Akagera announces positive Phase I data of AKG-100 in tuberculosis

Akagera Medicines has reported positive data from the SAD segment of its first-in-human Phase I trial of AKG-100, an investigational long-acting IV therapeutic targeting tuberculosis, including DR-TB.

The post Akagera announces positive Phase I data of AKG-100 in tuberculosis appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.